These 3 Things Are Impacting Monsanto Company (MON)’s Earnings by Estimize
Monsanto Company (MON) Materials – Chemicals | Reports April 6, Before Market Opens
Monsanto Company (MON) 2Q16 Earnings – Key Takeaways
- The Estimize community is looking for EPS of $2.53 on $4.81 billion in revenue, 8 cents higher than Wall Street on the bottom line and $27 million on the top
- Monsanto’s core business has been a hot button issue for years now and has contributed to its 5 consecutive misses on the top line
- Monsanto’s biggest obstacles lately include, a strong U.S. dollar, weak commodity prices and volatile glyphosate conditions
- What are you expecting for MON? Get your estimate in here!
Monsanto (MON), the leader in agrochemical and agricultural biotechnology, is scheduled to report FQ2 2016 earnings Wednesday, before the opening bell. Chemically and genetically modified products have been a point of contention the past 5 years, causing many agricultural companies to abandon their traditional means of harvesting. However, Monsanto remains stuck in its ways and continues to mass produce chemically infused products. As a result, shares have plummeted 24.2% on 5 consecutive quarters of missing its revenue target.
Lee Ainslie's Maverick Capital had a difficult third quarter, although many hedge funds did. The quarter ended with the S&P 500's worst month since the beginning of the COVID pandemic. Q3 2021 hedge fund letters, conferences and more Maverick fund returns Maverick USA was down 11.6% for the third quarter, bringing its year-to-date return to Read More
This quarter should continue the downward trend, as EPS is projected to fall 11% while sales are expected to decline 7%, on a year over year basis. Consequently, the Estimize community is looking for EPS of $2.53 on $4.81 billion in revenue, 8 cents higher than Wall Street on the bottom line and $27 million on top. However out Select Consensus, which heavily weights our most accurate analysts and recent estimates, is expecting a more modest beat of 1 cent. Monsanto is seeing rampant downward revisions activity lately, watching EPS fall 16% and revenue down 7% in the past three months. The current volatility in the global agro industry and strong U.S. dollar bode poorly for the remainder of Monsanto’s fiscal 2016.
Monsanto’s core business has been a hot button issue for years now and has recently caused revenue to slip. Monsanto is currently facing three major headwinds, namely currency headwinds, weak commodity prices and unfavorable glyphosate conditions. Like other multinationals, a strong U.S. dollar has put immense pressure on its revenues and margins. This is likely to continue through the remainder of fiscal 2016. Moreover, key markets such as Latin America and Canada have been hit with weak corn volume and glyphosate rates. Despite the current volatility, Monsanto is aggressively repurchasing shares and is in talks to takeover pharmaceutical giant, Bayer.
Do you think MON can beat estimates? There is still time to get your estimate in here!